Target intelligence / Profile preview

Family with sequence similarity 50 member A (FAM50A)

Target
FAM50A
Molecular classification
Other (spliceosomal-associated protein), DNA-binding protein, Putative transcription factor
01

Overview

Family with sequence similarity 50 member A (FAM50A) is a nuclear basic protein encoded on the X chromosome (Xq28) that contains a nuclear localization signal and can function as a DNA-binding protein or putative transcription factor[2][5]. FAM50A is an essential component of the spliceosome C complex and plays a role in pre-mRNA splicing, with particular relevance to neural development and craniofacial patterning as evidenced by knockout animal models[1]. Pathogenic mutations in FAM50A are the genetic cause of Armfield X-linked intellectual disability (XLID) syndrome, characterized by intellectual disability, developmental delay, distinctive facial features, and ophthalmological findings[1][3]. In cancer, FAM50A appears to act as a pro-oncogenic factor, promoting cell proliferation, migration, invasion, epithelial–mesenchymal transition, and resistance to apoptosis in hepatocellular carcinoma and possibly other tumors[2]. High FAM50A expression in HCC is associated with poor prognosis, enhanced immune cell infiltration, and resistance to certain therapies (e.g., reduced lenvatinib sensitivity), making it a potential biomarker and therapeutic target in oncology[2]. There is ongoing research into FAM50A's precise molecular roles, but it is currently not classified under traditional target classes such as enzyme, transporter, or receptor; rather, it is linked to RNA processing, transcriptional regulation, and tumor biology[1][2][5].

Other names
Protein FAM50ADXS9928EHXC26XAP5HXC-269FProtein HXC-26Protein XAP-5Armfield X-linked mental retardation syndromeMRXSA
02

Mechanism of action

Alteration of mRNA splicing and processing\nRegulation of epithelial–mesenchymal transition and cell proliferation in cancer[2]

03

Biological functions

RNA splicing/processingGene transcription regulationCell proliferationApoptosis regulationImmune response modulation
04

Disease associations

Neurodevelopmental disease (X-linked intellectual disability / Armfield XLID syndrome)Cancer (e.g., hepatocellular carcinoma, medullary breast cancer, chronic lymphocytic leukemia)
05

Safety considerations

Potential impairment of normal RNA splicing and neurodevelopmental pathways if targeted
06

Interacting drugs

Lenvatinib (modulation of sensitivity shown in hepatocellular carcinoma cells)[2]
07

Biomarkers

Prognostic marker in hepatocellular carcinoma (HCC) (high FAM50A predicts poorer prognosis and immune infiltration)[2]

Beyond the preview

Go deeper on Family with sequence similarity 50 member A (FAM50A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Family with sequence similarity 50 member A (FAM50A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call